{"name":"Vir Biotechnology, Inc.","slug":"vir","ticker":"VIR","exchange":"NASDAQ","domain":"vir.bio","description":"Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefell","hq":"San Francisco, CA","founded":0,"employees":"367","ceo":"Marianne De Backer","sector":"Biotech","stockPrice":8.99,"stockChange":-0.34,"stockChangePercent":-3.64,"marketCap":"$1.5B","metrics":{"revenue":68556000,"revenueGrowth":-7.6,"grossMargin":0,"rdSpend":455966000,"netIncome":-437987000,"cash":232185000,"dividendYield":0,"peRatio":-3.9,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"VIR-2482 patent cliff ($0.0B at risk)","drug":"VIR-2482","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"VIR-1111 patent cliff ($0.0B at risk)","drug":"VIR-1111","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Vir Biotechnology Announces FDA Fast Track Designation for VIR-2482","summary":"The FDA granted fast track designation to VIR-2482 for the treatment of COVID-19.","drugName":"VIR-2482","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Vir Biotechnology Reports Third Quarter 2023 Financial Results","summary":"The company reported a net loss of $143.8 million for the third quarter of 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"Vir Biotechnology Announces Collaboration with Pfizer to Develop and Commercialize VIR-1111","summary":"The companies will collaborate to develop and commercialize VIR-1111 for the treatment of COVID-19.","drugName":"VIR-1111","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9iNnczN0tFMUZzUkJVdEZwdG5FM2lxbjMzZlo2d2IxWEpGaGgzalVZc0NWb2F6X3lvbGJzUGJXNzB2QW9pcXdfU1F1MnNVbWNQanh1OE5jNWlEM2QyaV93aERINFE?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"VIR SEC Filings - Vir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"VIR SEC Filings - Vir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOZW9ydDdRVDNtNXFsSGtvbDNXYmxSNkZuQ2UwMVozT0FRWUlEaGFoMl9RYXhLYzA3RnNYdm9yeWRSdnNuckl5QWV5V21iZm94cGtHdTIyZlNsS3otQmlEWmhCOGs1QVJQUXJpNzBGV2lfanNEaTlSZGgzbDhGQm1HWHVmTEg5LUkxT0xrNlQ2YTIzckZISmEwX1JpTDdZdnhIeVBuRzIxSDlfd0R6Y1pQRmhtVU1iOTg?oc=5","date":"2026-02-25","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration - Genetic Engineering and Biotechnology News","headline":"Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSTljVXdEZDFkXzFGMnpDTVZLaEhtRFlic0NKbnhWcUtQTXBnMTZ6QW1JNzRIUmxqZ1RMTXJVS1BXSkliMUFIQzcxREpha3VEczZhWkp1WUFXRkRjRDliOU9LZnduUVlPN2dzU3N2WF9lYVp3Z29odGY1VFBEbDhDMmpDTWo2YlBQelZ5cWh0Q1phUDZycUhqcmZPdlBWZThLVVFoeTFHbHFyQmdoWTRpa3BQaUpYbGNfWm9fOVJkSDNQUUk?oc=5","date":"2026-02-24","type":"deal","source":"Pharmaceutical Executive","summary":"Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN - Pharmaceutical Executive","headline":"Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-X","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQVlZUeHAwbTEwWHJ1eWlIN1JEMHhMUF9qU1pJeDgxRU5NejV0Y3c0NWdnaUY1WEJaRnVMSnE1Z01aSllCcFphTXM1NFJxR0l6Tmk3bW42N2dnMG9vNXZEZG9vZEpJeTR3SFpyVVN4RVZJN1EwWUNBUWpZT0JvbkJJTXV4VWFOMjRVb29kV0NVemJnRDBsZ2Nv?oc=5","date":"2026-02-24","type":"deal","source":"Investor's Business Daily","summary":"Vir Biotech Catapults On Its $1.71 Billion Deal With Astellas - Investor's Business Daily","headline":"Vir Biotech Catapults On Its $1.71 Billion Deal With Astellas - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPU3BRY1R2THk5aF9lQnZaTGsyTHpwVFU1NnhtYVJTV3R2X3ZPY0ZjRzJieGxkb3lhRmVlMFQ2TU1feGNkZ2Q2THpzWlhTdmNNMFVySHdJWVl3MlYxQm0yc3Yxbk5ta1hBVS1qOWVkT3dQdUVlOU1hekVxc1VicEppSWNQQm9vSGtpN1MzdGZsZ21lRkp1Zzc3czJrTEJ4T2RSQ1ZnU2N3a0s2Vzg?oc=5","date":"2026-02-24","type":"deal","source":"Contract Pharma","summary":"Astellas Pharma, Vir Biotechnology Partner to Advance VIR-5500 - Contract Pharma","headline":"Astellas Pharma, Vir Biotechnology Partner to Advance VIR-5500","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNSC1QUUplNXdLTS1JYXlmY29PbzQ5dGtHbUl4TTlpRXk1M1pqQzVVaXAtMjEyWGZZTHRQTFpnYVp1bHFUaWxOOGRRRXJZc3ZseHBEbkNkbFR0U1F5ZmVNbERHU3M4Q0tTcmhpUDcyeHNYWkNRYWc5dXNUa0ZSTFhFUmlndlFoYnNVTURYdFJMZXRvR3RSMXllTDBBWlhVSUtmbklR?oc=5","date":"2026-02-24","type":"trial","source":"BioPharma Dive","summary":"Vir climbs on Astellas deal, study results for ‘masked’ T cell engager - BioPharma Dive","headline":"Vir climbs on Astellas deal, study results for ‘masked’ T cell engager","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOdEtJM0MzM3pFMzJyeGVoLTBld2pCZGJaR1kwZmtIcW9tOTBiOGZxNi1mVG5hdmRmMzgyYV9KUFRVMndwYWxGWEhZMFBnLWlpcjBUcTE3Y1R1NWo0UDkxM3ZkMnh2aDYwNUdlVERGU3UzaWs5aVMxUTNDZXJTSHdYZlhjQzBQcVU0cGRqbzBCendkQXNKaS04TjBseW95UW81SDlvZ1YxV0lMcjAyRVljVl9kMTV1TVhY?oc=5","date":"2026-02-24","type":"trial","source":"Seeking Alpha","summary":"Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish (VIR) - Seeking Alpha","headline":"Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish (VIR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPU0ZkR2NXMktwRkZyRnpuTExuNE1zNjRpSmJzQzB0N0NITksxdkU1VnRlZWlxX3pBMjZqdE8yZzJaNDBBdTR6d0g5ekc3OENDeHY5TExNZ3pmOXdPenU0S3VveW9YUm1LRHluRmRHVHhCRFBfNlBzc3lsV3pDcWJnczFuNUc5c0l6Q0Y4eHgwTU8yU0dsRHlXc1lOMGc5U21OMHFXZWJSU0VrSF94SktIMGtvLXY2NTB2cWZ5OFczd0QtNUhvUDZmM1RueVZxR21jaTZlTkppdGRXWHVBWEItNUo2Vjl6T1JuRDJoRkJVUGVEWGRRNU9HUUFTdEZWcFdqa0ppWVM0OG15VmZxc29TeU1DRnNwd1lJSjdIMWJtakpHSkg5QmRoaUxaZS1udnVwZjJkQklTRjg5UldiY2diSEtuVHJrVXcyT2E2TlpoYXYzREZM?oc=5","date":"2026-02-23","type":"deal","source":"PR Newswire","summary":"Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - PR Newswire","headline":"Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNaE01dHVfTjFDOWlUNHVtUFEzZDVRbUM2NzRGclR4N1hhYy1YakRQVVZraEYwYW1WTDM2bG91dVZWM2NmZDdiSTZtOWtLaW9nTUtUZDU1Vkt0ekhuZnh4OWpEMjNVSUxGX2xGajhyUmo4bGQ3SVZfT2dlUTVZaHhzYndDTUUwc1dYZEktWENJNllCSlRsM1VaenVxdGhXVFhNRlA5SWJSNnVVSHRhQ1JWZW45aFFad3JaczMwMHlpUkxaVmVvZEg3MjJ4UHpzXy1sY2p3N1pvOWxpTFFjM1NjSzRRSnlBSjk5YURaZlM4QkROVlU?oc=5","date":"2026-01-12","type":"pipeline","source":"BioSpace","summary":"Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones - BioSpace","headline":"Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestone","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVlp1WDg1YkJURXBGd0Z4d2w0Q3h4bWs0dVBfZ2Jvd1VURWUyNURkOUFDUXZrU2pFb01taWFaNUoxR3NCc1k1a3hfcm1faTRkZ1NhMUE5SHNUVks0X1k3U0Fpd3FNM2NrMVhYN1lfVUNjMmhqUzlXeHpTSW1IZXBfc0dqQlZzRHdmakNiUTUyUHFCblpsMFBWWUpmOGVkVExNOWV2WFVWdXE?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Norgine gets in on Vir's hepatitis D program with €550M European licensing pact - Fierce Biotech","headline":"Norgine gets in on Vir's hepatitis D program with €550M European licensing pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQaUptdWdONUh6alFuOURaRURWQk5pVVJUWjFTd1BEOENrRDBNVWhTSl9WcTU1dnFBOGFVdk1FTm1pR1gwOUt3OHdxeG81ckdUb2R4a0djd1M2TkNkeXlYVEo5ZUVnZTJKSEJiZlI2MWZXVDZuV3J2WnM4OE1xbUdUR25HQkRKWlpZenRaZVQ0eHl6Y3dGU2ZSQnVqaHRVY04xcFBselJIdVc?oc=5","date":"2025-12-17","type":"pipeline","source":"Latham & Watkins LLP","summary":"Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Latham & Watkins LLP","headline":"Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Latham & Watkins LLP","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-16","type":"deal","source":"Business Wire","summary":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECL","headline":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, ","sentiment":"neutral"}],"patents":[{"drugName":"VIR-2482","drugSlug":"monoclonal-antibody","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"VIR-1111","drugSlug":"monoclonal-antibody","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Regeneron Pharmaceuticals","Biogen"],"therapeuticFocus":["Infectious Diseases","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":68556000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":68556000,"period":"2025-12-31"},{"value":74205000,"period":"2024-12-31"},{"value":86180000,"period":"2023-12-31"},{"value":1615797000,"period":"2022-12-31"},{"value":1095415000,"period":"2021-12-31"},{"value":76368000,"period":"2020-12-31"}],"grossProfit":66494000,"grossProfitHistory":[{"period":"2025-12-31","value":66494000},{"period":"2024-12-31","value":62867000},{"period":"2023-12-31","value":36729000},{"period":"2022-12-31","value":1434153000}],"rdSpend":455966000,"rdSpendHistory":[{"period":"2025-12-31","value":455966000},{"period":"2024-12-31","value":506499000},{"period":"2023-12-31","value":579720000},{"period":"2022-12-31","value":474648000}],"sgaSpend":92074000,"operatingIncome":-479510000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-479510000},{"period":"2024-12-31","value":-552170000},{"period":"2023-12-31","value":-670746000},{"period":"2022-12-31","value":833068000}],"netIncome":-437987000,"netIncomeHistory":[{"period":"2025-12-31","value":-437987000},{"period":"2024-12-31","value":-521960000},{"period":"2023-12-31","value":-615061000},{"period":"2022-12-31","value":515837000}],"eps":-3.16,"epsHistory":[{"period":"2025-12-31","value":-3.16},{"period":"2024-12-31","value":-3.83},{"period":"2023-12-31","value":-4.59},{"period":"2022-12-31","value":3.83}],"cash":232185000,"cashHistory":[{"period":"2025-12-31","value":232185000},{"period":"2024-12-31","value":222947000},{"period":"2023-12-31","value":241576000},{"period":"2022-12-31","value":848631000}],"totalAssets":1002823000,"totalLiabilities":237547000,"totalDebt":97852000,"equity":765276000,"operatingCashflow":-391781000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-391781000},{"period":"2024-12-31","value":-446352000},{"period":"2023-12-31","value":-778785000},{"period":"2022-12-31","value":1663253000}],"capex":-4832000,"capexHistory":[{"period":"2025-12-31","value":-4832000},{"period":"2024-12-31","value":-7301000},{"period":"2023-12-31","value":-21573000},{"period":"2022-12-31","value":-68006000}],"freeCashflow":-396613000,"dividendsPaid":null,"buybacks":0,"employees":367,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":23339000,"ebit":-132290000,"ebitda":-129479000,"period":"2026-03-31","revenue":-41000,"epsBasic":-0.85,"netIncome":-125695000,"rdExpense":108922000,"epsDiluted":-0.85,"grossProfit":null,"operatingIncome":-132290000},{"sga":23616000,"ebit":-47921000,"ebitda":-45023000,"period":"2025-12-31","revenue":63760000,"epsBasic":-0.31,"netIncome":-42923000,"rdExpense":88349000,"epsDiluted":-0.31,"grossProfit":63734000,"operatingIncome":-47921000},{"sga":22231000,"ebit":-173443000,"ebitda":-170445000,"period":"2025-09-30","revenue":-65000,"epsBasic":-1.17,"netIncome":-163141000,"rdExpense":151463000,"epsDiluted":-1.17,"grossProfit":-54000,"operatingIncome":-173443000},{"sga":22283000,"ebit":-118589000,"ebitda":-115672000,"period":"2025-06-30","revenue":1031000,"epsBasic":-0.8,"netIncome":-110958000,"rdExpense":97509000,"epsDiluted":-0.8,"grossProfit":1020000,"operatingIncome":-118589000},{"sga":23944000,"ebit":-139557000,"ebitda":-136690000,"period":"2025-03-31","revenue":1794000,"epsBasic":-0.88,"netIncome":-120965000,"rdExpense":118645000,"epsDiluted":-0.88,"grossProfit":1794000,"operatingIncome":-139557000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":10594000,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.99,"previousClose":9.33,"fiftyTwoWeekHigh":11.66,"fiftyTwoWeekLow":4.16,"fiftyTwoWeekRange":"4.155 - 11.66","fiftyDayAverage":9.64,"twoHundredDayAverage":6.93,"beta":1.7,"enterpriseValue":1192802944,"forwardPE":-3.9,"priceToBook":1.64,"priceToSales":23.15,"enterpriseToRevenue":18.21,"enterpriseToEbitda":-2.65,"pegRatio":0,"ebitda":-451048992,"ebitdaMargin":0,"freeCashflow":-214927632,"operatingCashflow":-446051008,"totalDebt":95579000,"debtToEquity":11.8,"currentRatio":7.11,"returnOnAssets":-24.8,"returnOnEquity":-47.7,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":20.56,"targetHighPrice":30,"targetLowPrice":16,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6.6,"institutionHeldPercent":73.3,"sharesOutstanding":168651974,"floatShares":124716448,"sharesShort":16117209,"shortRatio":8.96,"shortPercentOfFloat":9.6,"epsTrailing":-3.13,"epsForward":-2.28,"revenuePerShare":0.47,"bookValue":5.49,"officers":[{"age":56,"name":"Dr. Marianne  De Backer M.B.A., M.Sc., Ph.D.","title":"President, CEO & Director"},{"age":56,"name":"Mr. Jason  O'Byrne M.B.A.","title":"Executive VP & CFO"},{"age":46,"name":"Ms. Vanina  de Verneuil J.D.","title":"Executive VP, General Counsel & Corporate Secretary"},{"age":77,"name":"Dr. Lawrence  Corey M.D.","title":"Co-Founder & Scientific Advisor"},{"age":null,"name":"Dr. Louis J. Picker M.D.","title":"Co-Founder & Scientific Advisor"},{"age":51,"name":"Mr. Brent  Sabatini","title":"Senior VP, Principal Accounting Officer & Chief Accounting Officer"},{"age":71,"name":"Dr. Maninder  Hora Ph.D.","title":"Executive VP & Chief Technical Operations Officer"},{"age":null,"name":"Dr. Jennifer Eileen Towne Ph.D.","title":"Executive VP & Chief Scientific Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.vir.bio","phone":"415 906 4324"}}